A Phase I/II Trial of Panobinostat in Combination with Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma

Based on previous studies demonstrating single agent efficacy with lenalidomide and panobinostat in patients with relapsed or refractory Hodgkin lymphoma (HL), we conducted a phase I/II study to evaluate the safety and efficacy of the combination in this patient population. The recommended phase 2 dose was 25 mg lenalidomide days 1-21 with 15 mg panobinostat TIW, and an ORR of 16.7% in patients was observed, with a durable response in one patient with lymphocyte predominant HL.

Source: Clinical Lymphoma, Myeloma and Leukemia - May 22, 2017 Category: Hematology Authors: Joseph J. Maly, Beth A. Christian, Xiaohua Zhu, Lai Wei, Jennifer L. Sexton, Samantha M. Jaglowski, Steven M. Devine, Todd A. Fehniger, Nina D. Wagner-Johnston, Mitch A. Phelps, Nancy L. Bartlett, Kristie A. Blum Source Type: research